Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P2X7 Receptor Occupancy by JNJ-54175446
NCT03088644Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-54175446 in major depressive disorder (MDD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Effective Radiation Dose Following Injection of 18F-JNJ-64413739 up to 4 Weeks, Total and Regional Brain Compartmental Kinetics for Volume of Distribution of 18F-JNJ-64413739 up to 4 Weeks and 3 more. Started Mar 2017; status: completed.
02
Drugs
JNJ-54175446
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03088644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088644.